drugset / Trial / NCT03074591

Effect of IV Iron in Patients With Heart Failure With Preserved Ejection Fraction

NCT03074591

RandomizedParallel-groupDouble-blindTreatment

Summary

This study addresses, whether treatment with IV iron for patients with heart failure with preserved ejection fraction (HFpEF) and iron deficiency (ID), both with or without anaemia, can improve exercise capacity as measured by 6-minute walking test (6-MWT) and symptoms while being safe

Timeline

Start
2017-08-01
Primary completion
2022-12-13
Completion
2024-04-10

Publications

  • Background von Haehling S, Doehner W, Evertz R, Garfias-Veitl T, Diek M, Karakas M, Birkemeyer R, Fillippatos G, Ponikowski P, Böhm M, Friede T, Anker SD. Iron deficiency in heart failure with preserved ejecton fracton: ratonale and design of the FAIR-HFpEF trial. Global Cardiol 2023; 1: 39-46.

Drugs

EvaluationDrugModalityDoseRoute
Comparator Ferric carboxymaltose Other / unclassified 50 mg/ml Intravenous